secwatch.observer — SEC 8-K summary
======================================

Issuer:     OptimizeRx Corp (OPRX)
CIK:        0001448431
Form:       8-K
Filed at:   2022-03-17T23:59:59+00:00
Accession:  0001213900-22-013267
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.02
LLM model:  deepseek-v4-flash:cloud@v2

OptimizeRx acquires EvinceMed assets for $2M cash and up to 240,741 shares
--------------------------------------------------------------------------

- Asset purchase of EvinceMed Corp.; total consideration includes $2M cash and up to 240,741 common shares.
- 185,185 shares issued at closing; 55,556 held back for 12 months for indemnification adjustments.
- Closing expected in Q2 2022; shares issued under Section 4(a)(2) exemption.
- Acquisition strengthens OptimizeRx's product offering in patient engagement technology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1448431/000121390022013267/0001213900-22-013267-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1448431/000121390022013267/ea157011-8k_optimizerx.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-013267

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer